ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this t ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology Q4 2025 financial results call and webcast. At this time, all par ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Speaker5Greetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the cal ...

Corporate Overview February 2026 NASDAQ GS ALXO © ALX Oncology Inc. All rights reserved. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall thereby any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 2 Confidential Forward-looking Statements Certain information set forth i ...

Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the P ...

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Teva Pharmaceutical Industries Ltd. (TEVA) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Teva Pharmaceutical Industries Ltd. is a member of our Medical group, which includes 925 different companies and currently sits at #8 in the Zacks Sector Rank ...

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biotech Summit F ...

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. F ...

Company Overview - ALX Oncology Holdings Inc. (ALXO) is part of the Medical sector, which includes 928 individual stocks and holds a Zacks Sector Rank of 10 [2] - ALX Oncology is currently rated with a Zacks Rank of 2 (Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for ALXO's full-year earnings has increased by 16.9%, reflecting improved analyst sentiment [4] - ALXO has returned approximately 81.4% year-to-date, significantly outperforming the average gain of 5.3% for Medical stocks [4] - In the Medical - Biomedical and Genetics industry, which includes 449 companies, ALXO is performing better than the average industry gain of 23.6% this year [6] Comparative Analysis - Another Medical stock, Amneal Pharmaceuticals (AMRX), has returned 15.2% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Amneal Pharmaceuticals belongs to the Medical - Drugs industry, which has a lower year-to-date gain of +2.7% and is ranked 146 [7]